Oncolytic adenoviruses: a game changer approach in the battle between cancer and the immune system.

References

• Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol ther. 2007;15(4):651–659.
   PubMed Web of Science ®Google Scholar
• Alberts P, Tilgase A, Rasa A, et al. The advent of oncolytic virotherapy in oncology: the Rigvir(R) story. Eur J Pharmacol. 2018;837:117–126.
   PubMed Web of Science ®Google Scholar
• Garber K. China approves world’s first oncolytic virus therapy for cancer treatment. J Natl Cancer Inst. 2006;98(5):298–300.
   PubMedGoogle Scholar
• Liang M. Oncorine, the world first oncolytic virus medicine and its update in China. Curr Cancer Drug Targets. 2018;18(2):171–176.
   PubMed Web of Science ®Google Scholar
• Cheng PH, Wechman SL, McMasters KM, et al. Oncolytic replication of E1b-deleted Adenoviruses. Viruses. 2015;7(11):5767–5779.
   PubMed Web of Science ®Google Scholar
• Pol J, Kroemer G, Galluzzi L. First oncolytic virus approved for melanoma immunotherapy. Oncoimmunology. 2016;5(1):e1115641.
   PubMed Web of Science ®Google Scholar
• Tang J, Shalabi A, Hubbard-Lucey VM. Comprehensive analysis of the clinical immuno-oncology landscape. Ann Oncol. 2018;29(1):84–91.
   PubMed Web of Science ®Google Scholar
• Chiocca EA, Rabkin SD. Oncolytic viruses and their application to cancer immunotherapy. Cancer Immunol Res. 2014;2(4):295–300.
   PubMed Web of Science ®Google Scholar
• Dharmadhikari N, Mehnert JM, Kaufman HL. Oncolytic virus immunotherapy for melanoma. Curr Treat Options Oncol. 2015;16(3):326.
   PubMed Web of Science ®Google Scholar
• Kepp O, Tesniere A, Schlemmer F, et al. Immunogenic cell death modalities and their impact on cancer treatment. Apoptosis. 2009;14(4):364–375.
   PubMed Web of Science ®Google Scholar
• Diaconu I, Cerullo V, Hirvinen ML, et al. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Cancer Res. 2012;72(9):2327–2338.
   PubMed Web of Science ®Google Scholar
• Hemminki A. Oncolytic immunotherapy: where are we clinically? Scientifica (Cairo). 2014;2014:862925.
   PubMedGoogle Scholar
• Tang D, Kang R, Coyne CB, et al. PAMPs and DAMPs: signal 0s that spur autophagy and immunity. Immunol Rev. 2012;249(1):158–175.
   PubMed Web of Science ®Google Scholar
• Kaufman HL, Kohlhapp FJ, Zloza A. Oncolytic viruses: a new class of immunotherapy drugs. Nat Rev Drug Discov. 2015;14(9):642–662.
   PubMed Web of Science ®Google Scholar
• Biswas M, Johnson JB, Kumar SR, et al. Incorporation of host complement regulatory proteins into Newcastle disease virus enhances complement evasion. J Virol. 2012;86(23):12708–12716.
   PubMed Web of Science ®Google Scholar
• Tomita K, Sakurai F, Iizuka S, et al. Antibodies against adenovirus fiber and penton base proteins inhibit adenovirus vector-mediated transduction in the liver following systemic administration. Sci Rep. 2018;8(1):12315.
   PubMedGoogle Scholar
• Ricca JM, Oseledchyk A, Walther T, et al. Pre-existing Immunity to oncolytic virus potentiates its immunotherapeutic efficacy. Mol ther. 2018;26(4):1008–1019.
   PubMed Web of Science ®Google Scholar
• Li X, Wang P, Li H, et al. The efficacy of oncolytic Adenovirus is mediated by T-cell responses against virus and tumor in Syrian hamster model. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(1):239–249.
   PubMed Web of Science ®Google Scholar
• Kanerva A, Nokisalmi P, Diaconu I, et al. Antiviral and antitumor T-cell immunity in patients treated with GM-CSF-coding oncolytic adenovirus. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19(10):2734–2744.
   PubMed Web of Science ®Google Scholar
• Mok W, Boucher Y, Jain RK. Matrix metalloproteinases-1 and −8 improve the distribution and efficacy of an oncolytic virus. Cancer Res. 2007;67(22):10664–10668.
   PubMed Web of Science ®Google Scholar
• Shen BH, Hermiston TW. Effect of hypoxia on Ad5 infection, transgene expression and replication. Gene Ther. 2005;12(11):902–910.
   PubMed Web of Science ®Google Scholar
• Hemminki O, Parviainen S, Juhila J, et al. Immunological data from cancer patients treated with Ad5/3-E2F-Delta24-GMCSF suggests utility for tumor immunotherapy. Oncotarget. 2015;6(6):4467–4481.
   PubMedGoogle Scholar
• Biedermann K, Vogelsang H, Becker I, et al. Desmoglein 2 is expressed abnormally rather than mutated in familial and sporadic gastric cancer. J Pathol. 2005;207(2):199–206.
   PubMed Web of Science ®Google Scholar
• Sachs MD, Rauen KA, Ramamurthy M, et al. Integrin alpha(v) and coxsackie adenovirus receptor expression in clinical bladder cancer. Urology. 2002;60(3):531–536.
   PubMed Web of Science ®Google Scholar
• Heise C, Kirn DH. Replication-selective adenoviruses as oncolytic agents. J Clin Invest. 2000;105(7):847–851.
   PubMed Web of Science ®Google Scholar
• Radko S, Jung R, Olanubi O, et al. Effects of Adenovirus Type 5 E1A isoforms on viral replication in arrested human cells. PloS one. 2015;10(10):e0140124.
   PubMed Web of Science ®Google Scholar
• DeWeese TL, van der Poel H, Li S, et al. A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. Cancer Res. 2001;61(20):7464–7472.
   PubMed Web of Science ®Google Scholar
• Hannen R, Bartsch JW. Essential roles of telomerase reverse transcriptase hTERT in cancer stemness and metastasis. FEBS Lett. 2018;592(12):2023–2031.
   PubMed Web of Science ®Google Scholar
• Chang J, Zhao X, Wu X, et al. A phase I study of KH901, a conditionally replicating granulocyte-macrophage colony-stimulating factor: armed oncolytic adenovirus for the treatment of head and neck cancers. Cancer Biol Ther. 2009;8(8):676–682.
   PubMed Web of Science ®Google Scholar
• Whyte P, Buchkovich KJ, Horowitz JM, et al. Association between an oncogene and an anti-oncogene: the adenovirus E1A proteins bind to the retinoblastoma gene product. Nature. 1988;334(6178):124–129.
   PubMed Web of Science ®Google Scholar
• Harbour JW, Dean DC. The Rb/E2F pathway: expanding roles and emerging paradigms. Genes Dev. 2000;14(19):2393–2409.
   PubMed Web of Science ®Google Scholar
• Tyagi S, Chabes AL, Wysocka J, et al. E2F activation of S phase promoters via association with HCF-1 and the MLL family of histone H3K4 methyltransferases. Mol Cell. 2007;27(1):107–119.
   PubMed Web of Science ®Google Scholar
• Pelka P, Miller MS, Cecchini M, et al. Adenovirus E1A directly targets the E2F/DP-1 complex. J Virol. 2011;85(17):8841–8851.
   PubMed Web of Science ®Google Scholar
• Heise C, Hermiston T, Johnson L, et al. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat Med. 2000;6(10):1134–1139.
   PubMed Web of Science ®Google Scholar
• Ranki T, Pesonen S, Hemminki A, et al. Phase I study with ONCOS-102 for the treatment of solid tumors - an evaluation of clinical response and exploratory analyses of immune markers. J Immunother Cancer. 2016;4:17.
   PubMed Web of Science ®Google Scholar
• Fueyo J, Gomez-Manzano C, Alemany R, et al. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene. 2000;19(1):2–12.
   PubMed Web of Science ®Google Scholar
• Pesonen S, Diaconu I, Kangasniemi L, et al. Oncolytic immunotherapy of advanced solid tumors with a CD40L-expressing replicating adenovirus: assessment of safety and immunologic responses in patients. Cancer Res. 2012;72(7):1621–1631.
   PubMed Web of Science ®Google Scholar
• Rojas JJ, Cascallo M, Guedan S, et al. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses. Gene Ther. 2009;16(12):1441–1451.
   PubMed Web of Science ®Google Scholar
• Olivier M, Hollstein M, Hainaut P. TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2010;2(1):a001008.
   PubMed Web of Science ®Google Scholar
• Pietsch EC, Sykes SM, McMahon SB, et al. The p53 family and programmed cell death. Oncogene. 2008;27(50):6507–6521.
   PubMed Web of Science ®Google Scholar
• Heise C, Sampson-Johannes A, Williams A, et al. ONYX-015, an E1B gene-attenuated adenovirus, causes tumor-specific cytolysis and antitumoral efficacy that can be augmented by standard chemotherapeutic agents. Nat Med. 1997;3(6):639–645.
   PubMed Web of Science ®Google Scholar
• Thomas MA, Nyanhete T, Tuero I, et al. Beyond oncolytics: E1B55K-deleted Adenovirus as a vaccine delivery vector. PloS one. 2016;11(7):e0158505.
   PubMed Web of Science ®Google Scholar
• Liu X, Cao X, Wei R, et al. Gene-viro-therapy targeting liver cancer by a dual-regulated oncolytic adenoviral vector harboring IL-24 and TRAIL. Cancer Gene Ther. 2012;19(1):49–57.
   PubMed Web of Science ®Google Scholar
• Jiang T, Zhou C, Ren S. Role of IL-2 in cancer immunotherapy. Oncoimmunology. 2016;5(6):e1163462.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Restifo NP. Adoptive cell transfer as personalized immunotherapy for human cancer. Science. 2015;348(6230):62–68.
   PubMed Web of Science ®Google Scholar
• Whiteside TL, Demaria S, Rodriguez-Ruiz ME, et al. Emerging opportunities and challenges in cancer immunotherapy. Clin Cancer Res off J Am Assoc Cancer Res. 2016;22(8):1845–1855.
   PubMed Web of Science ®Google Scholar
• Santos JM, Havunen R, Siurala M, et al. Adenoviral production of interleukin-2 at the tumor site removes the need for systemic postconditioning in adoptive cell therapy. Int J Cancer J Inter Du Cancer. 2017;141(7):1458–1468.
   PubMed Web of Science ®Google Scholar
• Bose A, Wong TW, Singh N. Formulation development and optimization of sustained release matrix tablet of Itopride HCl by response surface methodology and its evaluation of release kinetics. Saudi Pharm J. 2013;21(2):201–213.
   PubMed Web of Science ®Google Scholar
• Charych D, Khalili S, Dixit V, et al. Modeling the receptor pharmacology, pharmacokinetics, and pharmacodynamics of NKTR-214, a kinetically-controlled interleukin-2 (IL2) receptor agonist for cancer immunotherapy. PloS one. 2017;12(7):e0179431.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Frana LW, Sharrow SO, et al. In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2. J Iimmunol. 1985;134(1):157–166.
   PubMed Web of Science ®Google Scholar
• Hirvinen M, Rajecki M, Kapanen M, et al. Immunological effects of a tumor necrosis factor alpha-armed oncolytic adenovirus. Hum Gene Ther. 2015;26(3):134–144.
   PubMed Web of Science ®Google Scholar
• Havunen R, Siurala M, Sorsa S, et al. Oncolytic Adenoviruses armed with tumor Necrosis factor alpha and Interleukin-2 enable successful adoptive cell therapy. Mol Ther Oncolytics. 2017;4:77–86.
   PubMed Web of Science ®Google Scholar
• Du T, Shi G, Li YM, et al. Tumor-specific oncolytic adenoviruses expressing granulocyte macrophage colony-stimulating factor or anti-CTLA4 antibody for the treatment of cancers. Cancer Gene Ther. 2014;21(8):340–348.
   PubMed Web of Science ®Google Scholar
• Bramante S, Koski A, Kipar A, et al. Serotype chimeric oncolytic adenovirus coding for GM-CSF for treatment of sarcoma in rodents and humans. Int J Cancer J Inter Du Cancer. 2014;135(3):720–730.
   PubMed Web of Science ®Google Scholar
• Huang JH, Zhang SN, Choi KJ, et al. Therapeutic and tumor-specific immunity induced by combination of dendritic cells and oncolytic adenovirus expressing IL-12 and 4-1BBL. Mol ther. 2010;18(2):264–274.
   PubMed Web of Science ®Google Scholar
• Choi IK, Lee JS, Zhang SN, et al. Oncolytic adenovirus co-expressing IL-12 and IL-18 improves tumor-specific immunity via differentiation of T cells expressing IL-12Rbeta2 or IL-18Ralpha. Gene Ther. 2011;18(9):898–909.
   PubMed Web of Science ®Google Scholar
• Lee YS, Kim JH, Choi KJ, et al. Enhanced antitumor effect of oncolytic adenovirus expressing interleukin-12 and B7-1 in an immunocompetent murine model. Clin Cancer Res off J Am Assoc Cancer Res. 2006;12(19):5859–5868.
   PubMed Web of Science ®Google Scholar
• Ye JF, Qi WX, Liu MY, et al. The combination of NK and CD8+T cells with CCL20/IL15-armed oncolytic adenoviruses enhances the growth suppression of TERT-positive tumor cells. Cell Immunol. 2017;318:35–41.
   PubMed Web of Science ®Google Scholar
• Zafar S, Sorsa S, Siurala M, et al. CD40L coding oncolytic adenovirus allows long-term survival of humanized mice receiving dendritic cell therapy. Oncoimmunology. 2018;7(10):e1490856.
   PubMed Web of Science ®Google Scholar
• Andarini S, Kikuchi T, Nukiwa M, et al. Adenovirus vector-mediated in vivo gene transfer of OX40 ligand to tumor cells enhances antitumor immunity of tumor-bearing hosts. Cancer Res. 2004;64(9):3281–3287.
   PubMed Web of Science ®Google Scholar
• Calmels B, Paul S, Futin N, et al. Bypassing tumor-associated immune suppression with recombinant adenovirus constructs expressing membrane bound or secreted GITR-L. Cancer Gene Ther. 2004;12:198.
   Web of Science ®Google Scholar
• Dias JD, Hemminki O, Diaconu I, et al. Targeted cancer immunotherapy with oncolytic adenovirus coding for a fully human monoclonal antibody specific for CTLA-4. Gene Ther. 2012;19(10):988–998.
   PubMed Web of Science ®Google Scholar
• Tanoue K, Rosewell Shaw A, Watanabe N, et al. Armed oncolytic Adenovirus-expressing PD-L1 mini-body enhances antitumor effects of chimeric antigen receptor T Cells in solid tumors. Cancer Res. 2017;77(8):2040–2051.
   PubMed Web of Science ®Google Scholar
• Freedman JD, Hagel J, Scott EM, et al. Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies. EMBO Mol Med. 2017;9(8):1067–1087.
   PubMed Web of Science ®Google Scholar
• Martinez-Quintanilla J, He D, Wakimoto H, et al. Encapsulated stem cells loaded with hyaluronidase-expressing oncolytic virus for brain tumor therapy. Mol ther. 2015;23(1):108–118.
   PubMed Web of Science ®Google Scholar
• Ganesh S, Gonzalez Edick M, Idamakanti N, et al. Relaxin-expressing, fiber chimeric oncolytic adenovirus prolongs survival of tumor-bearing mice. Cancer Res. 2007;67(9):4399–4407.
   PubMed Web of Science ®Google Scholar
• Xiao T, Fan JK, Huang HL, et al. VEGI-armed oncolytic adenovirus inhibits tumor neovascularization and directly induces mitochondria-mediated cancer cell apoptosis. Cell Res. 2010;20(3):367–378.
   PubMed Web of Science ®Google Scholar
• Guse K, Diaconu I, Rajecki M, et al. Ad5/3-9HIF-Delta24-VEGFR-1-Ig, an infectivity enhanced, dual-targeted and antiangiogenic oncolytic adenovirus for kidney cancer treatment. Gene Ther. 2009;16(8):1009–1020.
   PubMed Web of Science ®Google Scholar
• Brachtlova T, van Beusechem VW. Unleashing the full potential of oncolytic Adenoviruses against cancer by applying RNA interference: the force awakens. Cells. 2018;7:12.
   Web of Science ®Google Scholar
• Zhang YF, Zhang BC, Zhang AR, et al. Co-transduction of ribosomal protein L23 enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in human gastric cancer. Oncol Rep. 2013;30(4):1989–1995.
   PubMed Web of Science ®Google Scholar
• Hall SJ, Canfield SE, Yan Y, et al. A novel bystander effect involving tumor cell-derived Fas and FasL interactions following Ad.HSV-tk and Ad.mIL-12 gene therapies in experimental prostate cancer. Gene Ther. 2002;9:511.
   PubMed Web of Science ®Google Scholar
• Pol JG, Acuna SA, Yadollahi B, et al. Preclinical evaluation of a MAGE-A3 vaccination utilizing the oncolytic Maraba virus currently in first-in-human trials. Oncoimmunology. 2019;8(1):e1512329.
   PubMed Web of Science ®Google Scholar
• Capasso C, Hirvinen M, Garofalo M, et al. Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and efficacy against melanoma. Oncoimmunology. 2016;5(4):e1105429.
   PubMed Web of Science ®Google Scholar
• Chaurasiya S, Chen NG, Fong Y. Oncolytic viruses and immunity. Curr Opin Immunol. 2018;51:83–90.
   PubMed Web of Science ®Google Scholar
• Prestwich RJ, Ilett EJ, Errington F, et al. Immune-mediated antitumor activity of reovirus is required for therapy and is independent of direct viral oncolysis and replication. Clin Cancer Res off J Am Assoc Cancer Res. 2009;15(13):4374–4381.
   PubMed Web of Science ®Google Scholar
• Hemminki O, Hemminki A. A century of oncolysis evolves into oncolytic immunotherapy. Oncoimmunology. 2016;5(2):e1074377.
   PubMed Web of Science ®Google Scholar
• Kelland LR. Of mice and men: values and liabilities of the athymic nude mouse model in anticancer drug development. Eur J Cancer. 2004;40(6):827–836.
   PubMed Web of Science ®Google Scholar
• Prendergast GC, Jaffee EM. Cancer immunologists and cancer biologists: why we didn’t talk then but need to now. Cancer Res. 2007;67(8):3500–3504.
   PubMed Web of Science ®Google Scholar
• Jiang H, Fueyo J. Healing after death: antitumor immunity induced by oncolytic adenoviral therapy. Oncoimmunology. 2014;3(7):e947872.
   PubMed Web of Science ®Google Scholar
• LaRocca CJ, Warner SG. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin Transl Med. 2018;7(1):35.
   PubMed Web of Science ®Google Scholar
• Liikanen I, Ahtiainen L, Hirvinen ML, et al. Oncolytic adenovirus with temozolomide induces autophagy and antitumor immune responses in cancer patients. Mol ther. 2013;21(6):1212–1223.
   PubMed Web of Science ®Google Scholar
• Seymour LW, Fisher KD. Oncolytic viruses: finally delivering. Br J Cancer. 2016;114(4):357–361.
   PubMed Web of Science ®Google Scholar
• Guedan S, Alemany R. CAR-T cells and oncolytic viruses: joining forces to overcome the solid tumor challenge. Front Immunol. 2018;9:2460.
   PubMed Web of Science ®Google Scholar
• Echavarria M. Adenoviruses in immunocompromised hosts. Clin Microbiol Rev. 2008;21(4):704–715.
   PubMed Web of Science ®Google Scholar
• Leen AM, Christin A, Khalil M, et al. Identification of hexon-specific CD4 and CD8 T-cell epitopes for vaccine and immunotherapy. J Virol. 2008;82(1):546–554.
   PubMed Web of Science ®Google Scholar
• Haveman LM, Bierings M, Legger E, et al. Novel pan-DR-binding T cell epitopes of adenovirus induce pro-inflammatory cytokines and chemokines in healthy donors. Int Immunol. 2006;18(11):1521–1529.
   PubMed Web of Science ®Google Scholar
• Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity. 2013;39(1):49–60.
   PubMed Web of Science ®Google Scholar
• Lee S, Margolin K. Tumor-infiltrating lymphocytes in melanoma. Curr Oncol Rep. 2012;14(5):468–474.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Spiess P, Lafreniere R. A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes. Science. 1986;233(4770):1318–1321.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Packard BS, Aebersold PM, et al. Use of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary report. N Engl J Med. 1988;319(25):1676–1680.
   PubMed Web of Science ®Google Scholar
• Besser MJ, Shapira-Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res off J Am Assoc Cancer Res. 2010;16(9):2646–2655.
   PubMed Web of Science ®Google Scholar
• Khammari A, Knol AC, Nguyen JM, et al. Adoptive TIL transfer in the adjuvant setting for melanoma: long-term patient survival. J Immunol Res. 2014;2014:186212.
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Kaikkonen S, Merisalo-Soikkeli M, et al. Favorable alteration of tumor microenvironment by immunomodulatory cytokines for efficient T-cell therapy in solid tumors. PloS one. 2015;10(6):e0131242.
   PubMed Web of Science ®Google Scholar
• Siurala M, Havunen R, Saha D, et al. Adenoviral delivery of tumor necrosis factor-alpha and interleukin-2 enables successful adoptive cell therapy of immunosuppressive Melanoma. Mol ther. 2016;24(8):1435–1443.
   PubMed Web of Science ®Google Scholar
• Rosenberg SA, Lotze MT, Muul LM, et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med. 1985;313(23):1485–1492.
   PubMed Web of Science ®Google Scholar
• Lotze MT, Chang AE, Seipp CA, et al. High-dose recombinant interleukin 2 in the treatment of patients with disseminated cancer. Responses, treatment-related morbidity, and histologic findings. Jama. 1986;256(22):3117–3124.
   PubMed Web of Science ®Google Scholar
• Mooradian MJ, Reuben A, Prieto PA, et al. A phase II study of combined therapy with a BRAF inhibitor (vemurafenib) and interleukin-2 (aldesleukin) in patients with metastatic melanoma. Oncoimmunology. 2018;7(5):e1423172.
   PubMed Web of Science ®Google Scholar
• Santos JM, Cervera-Carrascon V, Havunen R, et al. Adenovirus coding for interleukin-2 and tumor necrosis factor alpha replaces lymphodepleting chemotherapy in adoptive T cell therapy. Mol ther. 2018;26(9):2243–2254.
   PubMed Web of Science ®Google Scholar
• Havunen R, Santos JM, Sorsa S, et al. Abscopal effect in non-injected tumors achieved with cytokine-armed oncolytic adenovirus. Mol Ther Oncolytics. 2018;11:109–121.
   PubMed Web of Science ®Google Scholar
• Khammari A, Nguyen JM, Saint-Jean M, et al. Adoptive T cell therapy combined with intralesional administrations of TG1042 (adenovirus expressing interferon-gamma) in metastatic melanoma patients. Cancer Immunol Immunother. 2015;64(7):805–815.
   PubMed Web of Science ®Google Scholar
• Ping Y, Liu C, Zhang Y. T-cell receptor-engineered T cells for cancer treatment: current status and future directions. Protein Cell. 2018;9(3):254–266.
   PubMed Web of Science ®Google Scholar
• Kawakami Y, Eliyahu S, Delgado CH, et al. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor. Proc Natl Acad Sci U S A. 1994;91(9):3515–3519.
   PubMed Web of Science ®Google Scholar
• Hogquist KA, Jameson SC, Heath WR, et al. T cell receptor antagonist peptides induce positive selection. Cell. 1994;76(1):17–27.
   PubMed Web of Science ®Google Scholar
• Tahtinen S, Gronberg-Vaha-Koskela S, Lumen D, et al. Adenovirus improves the efficacy of adoptive T-cell therapy by recruiting immune cells to and promoting their activity at the tumor. Cancer Immunol Res. 2015;3(8):915–925.
   PubMed Web of Science ®Google Scholar
• Barrett DM, Grupp SA, June CH. Chimeric antigen receptor- and TCR-modified T cells enter main street and wall street. J Iimmunol. 2015;195(3):755–761.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Kuramitsu S, Posey AD Jr., et al. Expanding the therapeutic window for CAR T cell therapy in solid tumors: the knowns and unknowns of CAR T cell biology. Front Immunol. 2018;9:2486.
   PubMed Web of Science ®Google Scholar
• Townsend MH, Shrestha G, Robison RA, et al. The expansion of targetable biomarkers for CAR T cell therapy. J Exp Clin Cancer Res. 2018;37(1):163.
   PubMedGoogle Scholar
• Beatty GL, Haas AR, Maus MV, et al. Mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2014;2(2):112–120.
   PubMed Web of Science ®Google Scholar
• Sampson JH, Choi BD, Sanchez-Perez L, et al. EGFRvIII mCAR-modified T-cell therapy cures mice with established intracerebral glioma and generates host immunity against tumor-antigen loss. Clin Cancer Res off J Am Assoc Cancer Res. 2014;20(4):972–984.
   PubMed Web of Science ®Google Scholar
• Fraietta JA, Lacey SF, Orlando EJ, et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018;24(5):563–571.
   PubMed Web of Science ®Google Scholar
• Baitsch L, Fuertes-Marraco SA, Legat A, et al. The three main stumbling blocks for anticancer T cells. Trends Immunol. 2012;33(7):364–372.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell Therapy. Cancer Discov. 2018;8(10):1219–1226.
   PubMed Web of Science ®Google Scholar
• Fry TJ, Shah NN, Orentas RJ, et al. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy. Nat Med. 2018;24(1):20–28.
   PubMed Web of Science ®Google Scholar
• Watanabe K, Luo Y, Da T, et al. Pancreatic cancer therapy with combined mesothelin-redirected chimeric antigen receptor T cells and cytokine-armed oncolytic adenoviruses. JCI Insight. 2018;3:7.
   Web of Science ®Google Scholar
• Nishio N, Diaconu I, Liu H, et al. Armed oncolytic virus enhances immune functions of chimeric antigen receptor-modified T cells in solid tumors. Cancer Res. 2014;74(18):5195–5205.
   PubMed Web of Science ®Google Scholar
• Rosewell Shaw A, Porter CE, Watanabe N, et al. Adenovirotherapy delivering cytokine and checkpoint inhibitor augments CAR T cells against metastatic head and neck cancer. Mol ther. 2017;25(11):2440–2451.
   PubMed Web of Science ®Google Scholar
• Wing A, Fajardo CA, Posey AD Jr., et al. Improving CART-cell therapy of solid tumors with oncolytic virus-driven production of a bispecific T-cell engager. Cancer Immunol Res. 2018;6(5):605–616.
   PubMed Web of Science ®Google Scholar
• VanSeggelen H, Tantalo DG, Afsahi A, et al. Chimeric antigen receptor-engineered T cells as oncolytic virus carriers. Mol Ther Oncolytics. 2015;2:15014.
   PubMed Web of Science ®Google Scholar
• Marin-Acevedo JA, Dholaria B, Soyano AE, et al. Next generation of immune checkpoint therapy in cancer: new developments and challenges. J Hematol Oncol. 2018;11(1):39.
   PubMed Web of Science ®Google Scholar
• Ishida Y, Agata Y, Shibahara K, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo J. 1992;11(11):3887–3895.
   PubMed Web of Science ®Google Scholar
• Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734–1736.
   PubMed Web of Science ®Google Scholar
• Ledford H, Else H, Warren M. Cancer immunologists scoop medicine nobel prize. Nature. 2018;562(7725):20–21.
   PubMed Web of Science ®Google Scholar
• Hu-Lieskovan S, Ribas A. New combination strategies using programmed cell death 1/programmed cell death ligand 1 checkpoint inhibitors as a backbone. Cancer J. 2017;23(1):10–22.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
   PubMed Web of Science ®Google Scholar
• Nishino M, Ramaiya NH, Hatabu H, et al. Monitoring immune-checkpoint blockade: response evaluation and biomarker development. Nat Rev Clin Oncol. 2017;14(11):655–668.
   PubMed Web of Science ®Google Scholar
• Ribas A, Robert C, Hodi FS, et al. Association of response to programmed death receptor 1 (PD-1) blockade with pembrolizumab (MK-3475) with an interferon-inflammatory immune gene signature. J clin oncol. 2015;33(15_suppl):3001.
   Web of Science ®Google Scholar
• Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–567.
   PubMed Web of Science ®Google Scholar
• Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–1846.
   PubMed Web of Science ®Google Scholar
• Silva MA, Ryall KA, Wilm C, et al. PD-L1 immunostaining scoring for non-small cell lung cancer based on immunosurveillance parameters. PloS one. 2018;13(6):e0196464.
   PubMed Web of Science ®Google Scholar
• Cervera-Carrascon V, Siurala M, Santos JM, et al. TNFa and IL-2 armed adenoviruses enable complete responses by anti-PD-1 checkpoint blockade. Oncoimmunology. 2018;7(5):e1412902.
   PubMed Web of Science ®Google Scholar
• Zamarin D, Ricca JM, Sadekova S, et al. PD-L1 in tumor microenvironment mediates resistance to oncolytic immunotherapy. J Clin Invest. 2018;128(4):1413–1428.
   PubMed Web of Science ®Google Scholar
• Woller N, Gurlevik E, Fleischmann-Mundt B, et al. Viral infection of tumors overcomes resistance to pd-1-immunotherapy by broadening neoantigenome-directed T-cell responses. Mol ther. 2015;23(10):1630–1640.
   PubMed Web of Science ®Google Scholar
• Feola S, Capasso C, Fusciello M, et al. Oncolytic vaccines increase the response to PD-L1 blockade in immunogenic and poorly immunogenic tumors. Oncoimmunology. 2018;7(8):e1457596.
   PubMed Web of Science ®Google Scholar
• Cappuccini F, Stribbling S, Pollock E, et al. Immunogenicity and efficacy of the novel cancer vaccine based on simian adenovirus and MVA vectors alone and in combination with PD-1 mAb in a mouse model of prostate cancer. Cancer Immunol Immunother. 2016;65(6):701–713.
   PubMed Web of Science ®Google Scholar
• Speranza MC, Passaro C, Ricklefs F, et al. Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. Neuro Oncol. 2018;20(2):225–235.
   PubMed Web of Science ®Google Scholar
• Lang FF, Conrad C, Gomez-Manzano C, et al. Phase I study of DNX-2401 (Delta-24-RGD) oncolytic adenovirus: replication and immunotherapeutic effects in recurrent malignant glioma. J Clin Oncol. 2018;36(14):1419–1427.
   PubMed Web of Science ®Google Scholar
• Hunig T. The storm has cleared: lessons from the CD28 superagonist TGN1412 trial. Nat Rev Immunol. 2012;12(5):317–318.
   PubMed Web of Science ®Google Scholar
• Eriksson E, Milenova I, Wenthe J, et al. Shaping the Tumor stroma and sparking immune activation by CD40 and 4-1BB signaling induced by an armed oncolytic virus. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(19):5846–5857.
   PubMed Web of Science ®Google Scholar
• Jiang H, Rivera-Molina Y, Gomez-Manzano C, et al. Oncolytic adenovirus and Tumor-targeting immune modulatory therapy improve autologous cancer vaccination. Cancer Res. 2017;77(14):3894–3907.
   PubMed Web of Science ®Google Scholar
• McGray AJ, Bernard D, Hallett R, et al. Combined vaccination and immunostimulatory antibodies provides durable cure of murine melanoma and induces transcriptional changes associated with positive outcome in human melanoma patients. Oncoimmunology. 2012;1(4):419–431.
   PubMed Web of Science ®Google Scholar
• Zafar S, Parviainen S, Siurala M, et al. Intravenously usable fully serotype 3 oncolytic adenovirus coding for CD40L as an enabler of dendritic cell therapy. Oncoimmunology. 2017;6(2):e1265717.
   PubMed Web of Science ®Google Scholar
• Ogbomo H, Zemp FJ, Lun X, et al. Myxoma virus infection promotes NK lysis of malignant gliomas in vitro and in vivo. PloS one. 2013;8(6):e66825.
   PubMed Web of Science ®Google Scholar
• Bhat R, Dempe S, Dinsart C, et al. Enhancement of NK cell antitumor responses using an oncolytic parvovirus. Int J Cancer J Inter Du Cancer. 2011;128(4):908–919.
   PubMed Web of Science ®Google Scholar
• Zhang J, Tai LH, Ilkow CS, et al. Maraba MG1 virus enhances natural killer cell function via conventional dendritic cells to reduce postoperative metastatic disease. Mol ther. 2014;22(7):1320–1332.
   PubMed Web of Science ®Google Scholar
• Tai LH, de Souza CT, Belanger S, et al. Preventing postoperative metastatic disease by inhibiting surgery-induced dysfunction in natural killer cells. Cancer Res. 2013;73(1):97–107.
   PubMed Web of Science ®Google Scholar
• Kozlowska AK, Kaur K, Topchyan P, et al. Novel strategies to target cancer stem cells by NK cells; studies in humanized mice. Front Biosci. 2017;22:370–384.
   PubMed Web of Science ®Google Scholar
• Bhat R, Rommelaere J. Emerging role of natural killer cells in oncolytic virotherapy. Immunotargets Ther. 2015;4:65–77.
   PubMed Web of Science ®Google Scholar
• Wares JR, Crivelli JJ, Yun CO, et al. Treatment strategies for combining immunostimulatory oncolytic virus therapeutics with dendritic cell injections. Math Biosci Eng. 2015;12(6):1237–1256.
   PubMed Web of Science ®Google Scholar
• Kuryk L, Moller AW, Jaderberg M. Quantification and functional evaluation of CD40L production from the adenovirus vector ONCOS-401. Cancer Gene Ther. 2019 Feb;26(1-2):26–31.
   PubMed Web of Science ®Google Scholar
• Huebner RJ, Rowe WP, Schatten WE, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer. 1956;9(6):1211–1218.
   PubMed Web of Science ®Google Scholar
• Hemminki A. Crossing the valley of death with advanced cancer therapy. Helsinki: Nomerta Publishing; 2015.
   Google Scholar
• Racaniello VR, Baltimore D. Cloned poliovirus complementary DNA is infectious in mammalian cells. Science. 1981;214(4523):916–919.
   PubMed Web of Science ®Google Scholar
• Zheng X, Rao XM, Gomez-Gutierrez JG, et al. Adenovirus E1B55K region is required to enhance cyclin E expression for efficient viral DNA replication. J Virol. 2008;82(7):3415–3427.
   PubMed Web of Science ®Google Scholar
• Kirn D. Oncolytic virotherapy for cancer with the adenovirus dl1520 (Onyx-015): results of phase I and II trials. Expert Opin Biol Ther. 2001;1(3):525–538.
   PubMed Web of Science ®Google Scholar
• Hemminki A, Oksanen M, Merisalo-Soikkeli M. Oncolytic virotherapy trials–letter. Clin Cancer Res off J Am Assoc Cancer Res. 2013;19(16):4541–4542.
   PubMed Web of Science ®Google Scholar
• Taipale K, Liikanen I, Koski A, et al. Predictive and prognostic clinical variables in cancer patients treated with adenoviral oncolytic immunotherapy. Mol ther. 2016;24(7):1323–1332.
   PubMed Web of Science ®Google Scholar
• Bramante S, Kaufmann JK, Veckman V, et al. Treatment of melanoma with a serotype 5/3 chimeric oncolytic adenovirus coding for GM-CSF: results in vitro, in rodents and in humans. Int J Cancer J Inter Du Cancer. 2015;137(7):1775–1783.
   PubMed Web of Science ®Google Scholar
• Cerullo V, Pesonen S, Diaconu I, et al. Oncolytic adenovirus coding for granulocyte macrophage colony-stimulating factor induces antitumoral immunity in cancer patients. Cancer Res. 2010;70(11):4297–4309.
   PubMed Web of Science ®Google Scholar
• Koski A, Kangasniemi L, Escutenaire S, et al. Treatment of cancer patients with a serotype 5/3 chimeric oncolytic adenovirus expressing GMCSF. Mol ther. 2010;18(10):1874–1884.
   PubMed Web of Science ®Google Scholar
• Taipale K, Liikanen I, Juhila J, et al. Chronic activation of innate immunity correlates with poor prognosis in cancer patients treated with oncolytic adenovirus. Mol ther. 2016;24(1):175–183.
   PubMed Web of Science ®Google Scholar
• Chen DS, Mellman I. Elements of cancer immunity and the cancer-immune set point. Nature. 2017;541(7637):321–330.
   PubMed Web of Science ®Google Scholar
• Park BH, Hwang T, Liu TC, et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol. 2008;9(6):533–542.
   PubMed Web of Science ®Google Scholar
• Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther. 2001;8:89.
   PubMed Web of Science ®Google Scholar
• Berkeley RA, Steele LP, Mulder AA, et al. Antibody-neutralized reovirus is effective in oncolytic virotherapy. Cancer Immunol Res. 2018;6(10):1161–1173.
   PubMed Web of Science ®Google Scholar
• Scurr M, Pembroke T, Bloom A, et al. Low-dose cyclophosphamide induces antitumor T-cell responses, which associate with survival in metastatic colorectal cancer. Clin Cancer Res off J Am Assoc Cancer Res. 2017;23(22):6771–6780.
   PubMed Web of Science ®Google Scholar
• Moyo VM, Smith D, Brodsky I, et al. High-dose cyclophosphamide for refractory autoimmune hemolytic anemia. Blood. 2002;100(2):704–706.
   PubMed Web of Science ®Google Scholar